EICHORPublic-registry site landscape for NCT05490563, “STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia”, a Spinocerebellar Ataxia Type 3 study sponsored by Seelos Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05490563 (registry record) |
| Study title | STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia |
| Official title | A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia |
| Sponsor | Seelos Therapeutics, Inc. |
| Condition(s) | Spinocerebellar Ataxia Type 3 |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 23 |
| Site countries | United States, Australia, Brazil, Germany, Portugal, South Korea, Spain, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05490563.
Eichor generates a preliminary site-risk snapshot for NCT05490563 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Seelos Therapeutics, Inc.
← Eichor home · All tracked trials · Spinocerebellar Ataxia Type 3 studies · Weekly briefs
